Skip to main content
Premium Trial:

Request an Annual Quote

Phylos, Upstate To Develop New Protein Array Reagents

NEW YORK, June 5-The combinatorial biology company Phylos is working with Upstate, Inc to develop binding protein reagents for a new protein chip, the company said today.

 

In this arrangement, Upstate will market the chip. Phylos will receive research funding and milestone payments and royalties, if applicable.

 

Upstate, based in Waltham, Mass., develops drug discovery reagents, kits, and services based on cell signaling. It has kits for kinase activity screening and for Luminex's detection system.

 

Phylos is developing protein libraries for research into binding proteins, tissue proteomics, and therapeutics. The company is based in Lexington, Mass.

 

For further information, see the company press release.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.